The standard treatment for drug-sensitive TB is lengthy and complex. Dr. Sehulong Robert Moraba participated in research aimed at changing that as a Sub-Investigator for the NC-009 trial. This Phase 2, partially-blinded study assessed the safety and efficacy of a new drug, TBAJ876, in combination with pretomanid and linezolid, compared to a regimen containing bedaquiline.
Focused on adults with newly diagnosed, smear-positive pulmonary TB (SAHPRA ref: 20230301), this trial sought to identify shorter, simpler, and more effective oral regimens. Dr. Moraba’s clinical oversight was vital in monitoring participants on these novel combinations, contributing to the global effort to revolutionize first-line TB therapy.
